Antimicrob Agents Chemother. 2010;54:1627–32.PubMedCentralPubMedCrossRef 31. Snydman DR, Jacobus NV, McDermott LA. In vitro activity
of ceftaroline against check details a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2011;55:421–5.PubMedCentralPubMedCrossRef 32. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. CLSI document M100-S23 (ISBN1-56238-866-5). Wayne: Clinical and Laboratory Standards Institute; 2013. 33. EUCAST Breakpoint tables for interpretation of MICs and zone dimeters. Version 3.1. European Committee on Antimicrobial Susceptibility Testing 2013. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_3.1.pdf (Accessed 5 Feb 2013). 34. Drusano GL. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale Hedgehog inhibitor for improved anti-methicillin-resistant Staphylococcus aureus activity. J Antimicrob Chemother. 2010;65:iv33–9. 35. Keel RA, Crandon JL, Nicolau DP. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against
phenotypically diverse Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011;55:4028–32.PubMedCentralPubMedCrossRef 36. Sader HS, Flamm RK, Farrell DJ, Jones RN. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly Diflunisal patients: AWARE Ceftaroline Surveillance Program. Clin Infect Dis. 2012;55:S181–6.PubMedCrossRef 37. Pfaller MA, Farrell DJ, Sader HS, Jones RN. AWARE Ceftaroline Surveillance Program (2008–2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis. 2012;55:S187–93.PubMedCrossRef 38. Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus
aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008–2010). Clin Infect Dis. 2012;55:S206–14.PubMedCrossRef 39. Flamm RK, Sader HS, Farrell DJ, Jones RN. Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program. Clin Infect Dis. 2012;55:S194–205.PubMedCrossRef 40. Farrell DJ, Flamm RK, Jones RN, Sader HS. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). Diagn Microbiol Infect Dis. 2013;75:86–8.PubMedCrossRef 41. Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). Diagn Microbiol Infect Dis. 2013;76:61–8.PubMedCrossRef 42. Farrell DJ, Flamm RK, Sader HS, Jones RN.